HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IBRX
ImmunityBio, Inc.
There isn't enough reported data to score IBRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IBRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IBRX's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IBRX PE Valuation
IBRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IBRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBRX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IBRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.08 | -$0.68 |
| Q2 2026 | -$0.97 | -$0.50 |
| Q1 2026 | -$0.85 | -$0.28 |
| Q4 2025 | -$0.38 | +$0.24 |
| Q3 2025 | -$0.40 | +$0.51 |
| Q2 2025 | -$0.47 | +$0.49 |
| Q1 2025 | -$0.57 | +$0.51 |
| Q4 2024 | -$0.62 | +$0.53 |
IBRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IBRX on profitability, with a higher operating margin.
IBRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.8M | +52% |
| Q2 2026 | $51.2M | +94% |
| Q1 2026 | $44.2M | +168% |
| Q4 2025 | $38.3M | +407% |
| Q3 2025 | $32.1M | +425% |
| Q2 2025 | $26.4M | +2424% |
| Q1 2025 | $16.5M | +41193% |
| Q4 2024 | $7.6M | +5333% |
IBRX has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -160% | +14 points |
| Q2 2026 | -120% | +149 points |
| Q1 2026 | -158% | +232 points |
| Q4 2025 | -169% | +750 points |
| Q3 2025 | -174% | +1141 points |
| Q2 2025 | -270% | +9218 points |
| Q1 2025 | -390% | +237600 points |
| Q4 2024 | -919% | +60512 points |
IBRX's operating margin was −160% last quarter, up 14 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IBRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IBRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$78.3M | -$8.6M |
| Q2 2026 | -$70M | +$10.8M |
| Q1 2026 | -$77.1M | +$9.9M |
| Q4 2025 | -$71.3M | +$16M |
| Q3 2025 | -$69.6M | +$31.9M |
| Q2 2025 | -$80.8M | +$20.2M |
| Q1 2025 | -$87M | +$21.2M |
| Q4 2024 | -$87.3M | +$36M |
IBRX has burned cash in almost every quarter: −$297M over the past year, against −$325M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IBRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IBRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +10.9M shares |
| 1 year | +12% | +114M shares |
| 3 years | +143% | +623M shares |
| 5 years | +176% | +676M shares |
| Available history | +978% | +963M shares |
IBRX has 1.1B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IBRX Net Leverage
IBRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IBRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 29.3 | Neutral |
IBRX's weekly RSI is 39 (neutral) and its Stochastic is 29 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IBRX PE vs Healthcare Sector
IBRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IBRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.70 | 30% below |
| 20 week MA | $8.24 | 26% below |
| 50 week MA | $7.15 | 15% below |
| 100 week MA | $4.93 | 23% above |
| 200 week MA | $4.42 | 37% above |
IBRX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IBRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.74 | $16.0 | +328% |
| 2021 | $16.0 | $7.15 | -55% |
| 2022 | $7.15 | $5.46 | -24% |
| 2023 | $5.46 | $5.02 | -8.1% |
| 2024 | $5.02 | $2.78 | -45% |
| 2025 | $2.78 | $2.14 | -23% |
| 2026 YTD | $2.14 | $6.07 | +184% |
IBRX has the edge over HIMS on returns for 2026, with the stronger performance.